The trajectory of companies tied to the drug's legacy presents a complex investment scenario . While the initial surge generated substantial profits , generic alternatives have significantly eroded sales . Investing in connected pharmaceutical companies now requires a careful assessment of intellectual property protection , evolving medical shifts